AARDVARK THERAPEUTICS, INC.

Aardvark Therapeutics appoints Roy D. Baynes, M.D., Ph.D., and Susan E. Graf, RPh, MBA, to its Board. Baynes, with a history at Merck and Eikon Therapeutics, brings clinical development expertise. Graf offers biotech leadership and business strategy skills. Both aim to advance Aardvark's metabolic disease treatments.

Aardvark Therapeutics appoints Dr. Roy D. Baynes and Susan E. Graf to its Board, enhancing leadership for innovative metabolic disease therapies. ARD-101, targeting hunger suppression, is in Phase 3 for Prader-Willi Syndrome, reflecting Aardvark's commitment to addressing obesity-related conditions.